A shifting landscape: What will be next FDG in PET oncology?

Annals of Nuclear Medicine

Volumn 16, Issue 1, 2002, Pages 1-9

  Inoue, Tomio ^a   Oriuchi, Noboru ^b   Tomiyoshi, Katsumi ^c   Endo, Keigo ^b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c Nishidai Clinic Diagnostic Imaging Center   (Japan)

Author keywords

FDG; PET; PET oncology

Indexed keywords

ACETIC ACID; CARBON 11; CHOLINE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; METHIONINE; METIROSINE; TAMOXIFEN; TYROSINE;

ADULT; CANCER; CANCER LOCALIZATION; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG UPTAKE; FEMALE; HUMAN; MALE; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

ADULT; AMINO ACIDS; DNA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036213723     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02995285     Document Type: Review

References (81)

1. 18F]2-deoxy-2-fluoro-D-glucose
2. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer
3. Preoperative staging of non-small-cell lung cancer with positron emission tomography
4. Differential diagnosis of lung tumor with positron emission tomography. A prospective study
5. Detecting recurrent or residual lung cancer with FDG-PET
6. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with nonsmall cell lung cancer: A comparative study with X-ray computed tomography
7. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment
8. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial
9. 18F]FDG-PET a valid alternative to conventional diagnostic methods?
10. Whole body positron emission tomography in the treatment of Hodgkin disease
11. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: Is it time to shift gears?
12. 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer
13. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: The utility of positron emission tomography (PET)
14. PET imaging in oncology
15. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer
16. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings
17. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging
18. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: A prospective study based on primary surgery with extensive lymphadenectomy
19. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer
20. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma
21. Imaging features of primary and recurrent esophageal cancer at FDG PET
22. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma
23. Positron emission tomography scanning in malignant melanoma
24. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma
25. 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: A comparison of ultrasonographic and radiological methods of diagnosis
26. Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose
27. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient
28. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation
29. Surveillance for recurrent head and neck cancer using positron emission tomography
30. Head and neck cancer: Detection of recurrence with three-dimensional principal components analysis at dynamic FDG PET
31. Whole-body PET physiological and artifactual fluorodeoxyglucose accumulations
32. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography
33. Active and passive mechanisms of [fluorine-18]fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: A microautoradiographic study
34. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake
35. Methionine uptake by tumor tissue: A microautoradiographic comparison with FDG
36. 3H]thymidine, and gallium-67
37. Related Articles Cerebral glioma: Evaluation with methionine PET
38. Differential diagnosis of lung tumor with positron emission tomography: A prospective study
39. Carbon-11-methionine uptake in squamous cell head and neck cancer
40. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors
41. PET with L-[1-carbon-11]-tyrosine to visualize tumors and measure protein synthesis rates
42. 11C]-tyrosine imaging of soft-tissue tumors before and after therapy
43. 11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer
44. Nodal spread of squamous cell carcinoma of the oral cavity detected with PET-tyrosine, MRI and CT
45. 11C]tyrosine positron emission tomography to localization of cerebral gliomas for biopsy
46. 18F)fluorotyrosine
47. 18F]fluorotyrosine, a new PET tracer of protein synthesis
48. 123I]iodo-alpha-methyl tyrosine and SPECT
49. 18F-alpha-methyltyrosine using a separation and purification system
50. Biodistribution studies on [L-3-[fluorine-18]fluoro-a-methyl tyrosine: A potential tumor-detecting agent
51. 18F alpha-methyl tyrosine PET studies in patients with brain tumors
52. Detection of malignant tumors: Whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG-preliminary study
53. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyl-tyrosine: Comparison with fluorine-18 fluorodeoxyglucose PET
54. Radiolabeled amino acids: Basic aspects and clinical applications in oncology
55. Brain tumors: Detection with C-11 choline PET
56. 11C]choline
57. PET imaging of prostate cancer using carbon-11-choline
58. 18F-fluorodeoxyglucose: A novel method of preoperative lymph node staging
59. 11C-choline PET
60. 11C]choline; implications for in vivo imaging with positron emission tomography
61. 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer
62. 18F-fluoroethylcholine in prostate cancer imaging
63. 11C acetate
64. Carbon-11-thymidine and FDG to measure therapy response
65. 76Br]bromodeoxyuridine
66. 18]FLT and positron emission tomography
67. 67Ki proliferation index
68. 18F-FLT for breast cancer imaging
69. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma
70. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography
71. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil
72. Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma
73. Steroid-hormone receptors in breast cancer
74. The role of tamoxifen in the treatment and prevention of breast cancer
75. 18F]fluoro-17 beta-estradiol uptake in metastatic breast carcinoma
76. Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptor assays
77. Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer
78. 18F]fluoro-17 beta-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy
79. 18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: Preliminary study
80. Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir
81. PET the merging of biology and imaging into molecular imaging